Dose specification in External Beam Radiotherapy for CyberKnife and VMAT techniques applied to a case of prostate cancer
Abstract
Recent technological development in radiotherapy allows to introduce new irradiation techniques implemented on the conventional accelerators and on the machines such as CyberKnife (CK). These significantly changes the philosophy of planning and execution of radiotherapy. One of the fundamental concepts in radiotherapy is to define the therapeutic dose. It can be defined in the point, at the selected isodose, as an average value, or combined with the volume. We present the case of prostate cancer patient irradiated using CK machine and classic accelerator (VMAT). The differences in dose distribution and its value are shown. The analysis indicates that the average dose in Planning Treatment Volume (PTV) is a useful parameter during comparison of the dose distributions realized on machines of different type.
Keywords: prescribed dosenormalizationdose volume histogram (DVH)
References
- Yu CX, Tang G. Intensity-modulated arc therapy: principles, technologies and clinical implementation. Phys Med Biol. 2011; 56(5): R31–R54.
- Yartsev S, Muren L, Thwaites D. Treatment planning studies in radiotherapy. Radiotherapy and Oncology. 2013; 109(3): 342–343.
- King CR, Lehmann J, Adler JR, et al. CyberKnife radiotherapy for localized prostate cancer: rationale and technical feasibility. Technol Cancer Res Treat. 2003; 2(1): 25–30.
- Murray LJ, Cosgrove V, Lilley J, et al. Developing a class solution for Prostate Stereotactic Ablative Body Radiotherapy (SABR) using Volumetric Modulated Arc Therapy (VMAT). Radiother Oncol. 2014; 110(2): 298–302.
- Williams G, Tobler M, Leavitt D. Pitfalls in normalization for intensity-modulated radiation therapy planning. Med Dosim. 2005; 30(4): 194–200.
- losarek K, Tarnawski R, Maciejewski B. Is there need for inhomogeneous dose distribution? New concept of IMRS. 7th International Meeting on Progress in Radio-Oncology (ICRO/ÖGRO 7) Salzburg, 2002.
- Maciejewski B, Skołyszewski J, Majewski S, et al. Applicability of the biological isodoses „IzoBioGy-2” for tumour and normal tissue response for fractionated radiotherapy. Nowotwory. 1988; 37: 241–249.
- Chappell R, Fowler J, Ritter M, et al. Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys. 2001; 50(4): 1021–1031.
- Ślosarek K, Rembielak A, Grządziel A et al. New possibility In IMRT treatment planning, 9 th Varian European Users Meeting Sardinia, 7-9.06.2001.
- Slosarek K, Zajusz A, Szlag M. Comparison of traditional and simultaneous IMRT boost technique basing on therapeutic gain calculation. Med Dosim. 2008; 33(4): 299–302.
- Wu Q, Djajaputra D, Liu HH, et al. Optimization of intensity-modulated radiotherapy plans based on the equivalent uniform dose. Int J Radiat Oncol Biol Phys. 2002; 52(1): 224–235.
- A Prescription Template for RTOG Protocols. http://www.rtog.org/ LinkClick.aspx?fileticket=v-QYwJs2HaU%3d&tabid=197.
- Ferro M, Cilla S, Macchia G, et al. On the cutting edge of intensity modulated radiotherapy and simultaneous integrated boost (IMRT-SIB): The case of a patient with 8 brain metastases. Rep Pract Oncol Radiother. 2015; 20(4): 316–319.
- IRCU 83.
- Głowacki G, Miszczyk L, Blamek S. Protocol of radical fractionated stereotactic radiosurgery CyberKnife, patients with prostate cancer. Center of Oncology — MSC Memorial Institute, Branch , Gliwice 2013.
- Ślosarek K, Osewski W, Grządziel A, et al. Integral dose: Comparison between four techniques for prostate radiotherapy. Rep Pract Oncol Radiother. 2015; 20(2): 99–103.
- Osewski W, Ślosarek K, Karaszewska B. Dose distribution transfer from CyberKnife to Varian treatment planning system. Journal of Physics: Conference Series. 2014; 489: 012056.
- ŚLOSAREK K, GRZĄDZIEL A, SZLAG M, et al. Radiation Planning Index for dose distribution evaluation in stereotactic radiotherapy. Reports of Practical Oncology & Radiotherapy. 2008; 13(4): 182–186.
- Maciejewski B, Ślosarek K. Zastosowanie w radioterapii wzorów dawek równoważnych . NSD, TDF, CRE. Centrum Onkologii — Instytut im. M. Skłodowskiej-Curie, Gliwice 1979.